Full Breakdown
Lawsuits Claim GLP-1 Weight-Loss Drugs May Cause Rare Vision-Loss Condition NAION
By Drooid · · How we work
Core Event: Surge in U.S. Litigation Over GLP-1-Associated NAION
Thousands of patients have filed personal-injury lawsuits in state and federal courts alleging that GLP-1 receptor agonists—including Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity and related products—triggered non-arteritic anterior ischemic optic neuropathy (NAION), a sudden, often permanent loss of vision. A consolidated multidistrict litigation (MDL 3094) now contains roughly 3,848 pending cases as of July 1, 2026, up from 3,363 reported on March 2. Plaintiffs contend manufacturers failed to warn of this risk, which appears on product information in the EU, UK, Denmark, Australia and New Zealand but not on U.S. labels.
Background & Context
GLP-1 drugs lower blood glucose and suppress appetite, driving rapid adoption for type 2 diabetes and obesity. NAION is an “eye stroke” caused by reduced blood flow to the optic nerve; it most commonly affects people over age 50 and occurs in about 2–10 per 100,000 in that age group, but less than 1 per 100,000 in the general population. The European Medicines Agency (EMA) classifies NAION as a “very rare” adverse reaction to semaglutide, estimating a risk of up to 1 case per 10,000 treated patients. The U.S. FDA is reviewing the signal through its Sentinel Initiative but has not issued a formal warning.
Official Statements & Responses
Novo Nordisk and Eli Lilly assert that extensive clinical-trial data and real-world experience demonstrate a well-established safety profile for their GLP-1 products. In a joint 2024 filing the companies said the known risks are reflected in FDA-approved labeling, which the agency has reviewed more than 40 times. Both firms deny a causal link to NAION and emphasize ongoing safety monitoring. Australia’s Therapeutic Goods Administration (TGA) advises clinicians not to discontinue GLP-1 therapy solely because of NAION concerns, echoing the AAO’s stance. The EMA’s 2025 recommendation to add NAION as a very rare side effect reflects a more precautionary regulatory approach.
On-the-Ground Reports
Patients describe abrupt vision changes after months of GLP-1 use. A 63-year-old Pennsylvania man, prescribed Ozempic for diabetes in 2023, reported loss of vision in one eye after four months and total blindness in the other by October 2024, prompting him to surrender his commercial driver’s license. Plaintiffs allege the manufacturers knew—or should have known—about an increased NAION risk and failed to disclose it.
Conflicting Reports & Gaps
Scientific findings remain mixed. Studies published in JAMA Ophthalmology (2024) and Diabetes, Obesity and Metabolism (2025) identified a statistical association between semaglutide and NAION but stopped short of proving causation. Conversely, Novo-funded research (April 2025) and analyses in the American Journal of Ophthalmology reported no significant correlation. Observational designs dominate the literature, limiting the ability to separate drug effects from underlying risk factors such as diabetes, hypertension, sleep apnea and obesity. No randomized trial has definitively linked GLP-1 therapy to NAION, and the FDA has not concluded that a causal relationship exists.
What’s Next
The next major procedural milestone is a Rule 702 expert hearing scheduled for September 10-18, 2026, where courts will decide whether scientific experts may testify on general causation and warning adequacy. The FDA’s Sentinel review continues without a set completion date. Both Novo Nordisk and Eli Lilly have pledged to monitor emerging data and to defend the lawsuits vigorously, as reported on September 19.